eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

Monitoring and annual patient review

Freedom from INR monitoring1

Although treatment with ELIQUIS does not require routine monitoring of exposure, a calibrated, quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of ELIQUIS exposure may help to inform clinical decisions, e.g. overdose and emergency surgery.1

Annual review for patients with NVAF2

NICE Guideline CG180 (2014) recommends that patients with NVAF receive a review of their anticoagulant needs at least once a year.2

NICE AF Clinical Guideline (CG180, 2014)
"For people who are taking an anticoagulant review the need for anticoagulation and the quality of anticoagulation at least annually, or more frequently if clinically relevant events occur affecting anticoagulation or bleeding risk"2


It’s simple to switch your patients to ELIQUIS1

Stay on top of ELIQUIS product updates

Download guides designed for your patients

Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

INR = International Normalised Ratio   
NICE = National Institute of Health and Care Excellence   
NVAF = Non-Valvular Atrial Fibrillation


  1. ELIQUIS® (apixaban) Summary of Product Characteristics.
  2. NICE clinical guideline 180. Atrial fibrillation: management. June 2014. Last updated August 2014. Available at https://www.nice.org.uk/guidance/cg180. Last accessed February 2019.